牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-017871 Act: 34 Size: 30 KB 网页链接
$灿菲特生物制药(CANF)$ D Notice of Exempt Offering of Securities, item 06b Accession Number: 0001213900-20-017807 Act: 33 Size: 12 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-017501 Act: 34 Size: 26 KB 网页链接
$灿菲特生物制药(CANF)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001213900-20-016934 Act: 33 Size: 532 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-016932 Act: 34 Size: 498 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-016669 Act: 34 Size: 31 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-016229 Act: 34 Size: 45 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-016175 Act: 34 Size: 2 MB 网页链接
$灿菲特生物制药(CANF)$ D Notice of Exempt Offering of Securities, item 06b Accession Number: 0001213900-20-015364 Act: 33 Size: 12 KB 网页链接